A randomized controlled study on the efficacy and safety of clearing heat and dispelling dampness formula granules compared with traditional tonics in the treatment of hyperuricemia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400081315

Enrollment

Unknown

Registered

2024-02-28

Start date

2024-04-30

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Clearing heat and dispelling dampness formula granule group:Clearing heat and dispelling dampness granules 1 day/dose + Benzbromarone tablet simulant 50mg/day for 8 weeks.

Clearing heat and dispelling dampness traditional soup group:Clearing heat and dispelling dampness traditional soup 1 day/dose + Benzbromarone tablet simulant 50mg/day for 8 weeks.

Benzbromarone group:Benzbromarone tablets 50mg/day + clearing heat and dispelling dampness formula granules simulating medicine 1 day/dose for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (i) meet the western medical diagnostic criteria for hyperuricemia; (ii) meet the diagnostic criteria for Damp-Heat Embedded Conjunctivitisation Certificate of Traditional Chinese Medicine; (iii) aged 18-60 years old; (iv) voluntarily participated in the study and signed the informed consent form

Exclusion criteria

Exclusion criteria: ? Secondary hyperuricemia; ? Patients with kidney stones; ? Combined application of theophylline drugs and other uric acid-lowering drugs, such as imidazathioprine, 6-mercaptopurine, other salicylates containing aspirin (>300mg/d), oral contraceptives or hormone replacement therapy (prednisone dosage of >10mg/d) in the 3 months before the test; ? Patients with severe functional insufficiency of heart, brain, liver, kidney and other vital organs and malignant tumors; ? Psychiatric patients, long-term alcoholism, drug abuse; ?Pregnant or breastfeeding; ?Those who are allergic or have a history of allergy to the components of the study drug; (8) Participating in other clinical trials that affect the evaluation of the results of this study.

Design outcomes

Primary

Measure	Time frame
uric acid;	—

Secondary

Measure	Time frame
Metabolic indicators;	—

Countries

China

Contacts

Public ContactGuanjie Fan

Guangdong Provincial Hospital of Chinese Medicine

fanguanjie@gzucm.edu.cn+86 139 2511 9990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026